UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 6, 2014
METABOLIX, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE
(State or Other Jurisdiction of Incorporation)
|
001-33133 |
|
04-3158289 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
21 Erie Street, Cambridge, Massachusetts |
|
02139 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(617) 583-1700
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
EXHIBIT 99.1 |
Item 2.02 Results Of Operations and Financial Condition.
On August 6, 2014, Metabolix, Inc. issued a press release announcing the financial results for its quarter ended June 30, 2014. A copy of the press release is attached hereto as Exhibit 99.1. This information, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
|
|
No. |
|
Description |
|
99.1 |
|
Press Release dated August 6, 2014. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
METABOLIX, INC. |
|
Date: August 6, 2014 |
By: |
/s/ Joseph D. Hill |
|
|
|
Joseph D. Hill |
|
|
|
Chief Financial Officer |
|
Exhibit |
|
|
|
No. |
|
Description |
|
99.1 |
|
Press Release dated August 6, 2014. |
Exhibit 99.1
Metabolix Announces Second Quarter 2014 Financial Results
CAMBRIDGE, Mass. — Aug. 6, 2014 — Metabolix, Inc. (NASDAQ: MBLX), an advanced biomaterials company focused on sustainable solutions for the plastics and chemicals industries, today reported financial results for the three months ended June 30, 2014.
“As announced earlier this week, we have entered into a private placement agreement for $25 million of new equity financing, contingent upon obtaining a financial viability exception for the transaction from NASDAQ. Assuming we get the NASDAQ exception, we plan to deploy this capital to continue executing our business plan and building an intermediate-scale specialty polymers business based on our PHA biopolymer additives, that will serve as the foundation for our longer-range plans and the future growth of our business,” said Joseph Shaulson, president and CEO of Metabolix.
“Operationally, we made good progress during the second quarter, as key customers ramped up commercial-scale trials of our PHA biopolymer products and we increased our pipeline of customers testing products in a variety of applications,” Shaulson continued. “In the past several months, we have seen increasing interest and engagement with potential customers in the areas of PVC, PLA, latex coatings and micropowders, which underscores the value proposition of our innovative PHA products.
“We remain focused on securing financing, building market demand for our PHA products, and on having manufacturing up and running in 2015 to support an intermediate-scale biopolymers business. Once the private placement is completed, we plan to move forward with a preliminary engineering study and implementation planning for the retrofit of an existing contract manufacturing facility we have targeted for commercial PHA production. Successful completion of this study will enable us to progress to a detailed budget, definitive schedule and commercial contract for PHA manufacturing startup in 2015,” Shaulson added.
SECOND QUARTER 2014 FINANCIAL OVERVIEW
Metabolix manages its finances with an emphasis on cash flow and deploys its financial resources in a disciplined manner to achieve its key strategic objectives and to maximize value from its technology and product portfolio. The Company ended the second quarter of 2014 with $5.5 million in unrestricted cash and cash equivalents. The Company’s net cash used in operating activities during the second quarter of 2014 was $4.9 million, compared with $5.8 million in the second quarter of 2013.
Metabolix requires significant additional funding. Earlier in 2014, the Company indicated it would seek to raise $50 to $60 million to fund its business plan and that such financing might be accomplished in stages. On August 4, 2014, Metabolix announced that it entered into a private placement agreement with investors for the sale of an aggregate of $25 million of Company securities. The closing of the private placement is subject to the Company obtaining a financial viability exception from certain NASDAQ shareholder approval requirements under Rule 5635(f) of the NASDAQ Stock Market Listing Rules, as well as other customary closing conditions.
For the second quarter of 2014, the Company reported a net loss of $7.2 million, or $0.21 per share, compared with a net loss of $7.9 million, or $0.23 per share, for the second quarter of 2013.
Total revenue in the second quarter of 2014 was $1.2 million, compared with $1.7 million for the second quarter of 2013. Second quarter 2014 revenue consisted primarily of revenue from product sales and government grants. Biopolymer product orders of $0.6 million were shipped and billed during the quarter. The Company recognized $0.7 million in product revenue during the quarter, primarily from product shipments made during the first quarter of 2014, compared with $0.8 million in product revenue recognized during the second quarter of 2013. Cost of product revenue was $0.8 million during the quarter ended June 30, 2014 compared with $1.2 million for the comparable period in 2013.
Research and development expenses were $4.5 million for the second quarter of 2014, compared with $4.9 million for the same period in 2013. Selling, general and administrative expenses were $3.2 million and $3.4 million for the second quarters of 2014 and 2013, respectively.
For the first half of 2014, the Company reported a net loss of $15.4 million, or $0.44 per share, compared with a net loss of $14.6 million, or $0.43 per share, for the first half of 2013.
Total revenue during the first six months of 2014 was $2.2 million, compared with $3.6 million for the comparable period in 2013. Cost of product revenue was $1.5 million during the six months ended June 30, 2014, compared with $1.8 million for the comparable period in 2013.
Research and development expenses were $9.4 million during the first six months of 2014, compared with $9.8 million for the same period in 2013. Selling, general and administrative expenses were $6.8 million for the six-month period ended June 30, 2014 compared with $6.7 million for the first six months of 2013.
The Company’s net cash used in operating activities during the first half of 2014 was $13.8 million, which represents a decrease in cash used for operating activities from cash use of $14.3 million for the comparable period in 2013.
Conference Call Information
Metabolix management will host a conference call today at 4:30 p.m. (ET) to discuss the results of the second quarter. The Company also will provide an update on the business and answer questions from the investment community. A live webcast of the call with slides can be accessed through the Company’s website at http://www.metabolix.com in the investor relations section. To participate in the call, dial toll-free 877-709-8155 or 201-689-8881 (international).
To listen to a telephonic replay of the conference call, dial toll-free 877-660-6853 or 201-612-7415 (international) and enter pass code 13588304. The replay will be available beginning at 7:30 p.m. (ET) on Wednesday, August 6, 2014 and will last through 11:59 p.m. (ET) on Wednesday, August 20, 2014. In addition, the webcast will be archived on the Company’s website in the investor relations section.
About Metabolix
Metabolix, Inc. is an advanced biomaterials company focused on sustainable solutions for the plastics and chemicals industries. The Company is developing and commercializing a family of high-performance biopolymers targeted at applications for performance additives that can improve performance and/or reduce cost in other material systems such as PVC, PLA and coated paper. Metabolix also is developing platforms for biobased chemicals based on its novel “FAST” recovery process and for co-producing plastics, chemicals and energy from crops. Metabolix has established an industry-leading intellectual property portfolio that, together with its knowledge of advanced industrial practice, provides a foundation for industry collaborations.
For more information, please visit www.metabolix.com. (MBLX-E)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, statements about the terms, timing, completion and effects of the proposed financing and the Company’s intended use of proceeds therefrom, statements regarding the Company’s business plans and strategies; expectations for establishing commercial PHA biopolymer manufacturing; expected market demand and commercialization plans for the Company’s PHA biopolymer products; expected future financial results and cash requirements; plans for obtaining additional funding; plans and expectations that depend on the Company’s ability to continue as a going concern; and expectations for future research, product development and collaborations constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Metabolix’s filings with the Securities and Exchange Commission, including its 10-K for the year ended December 31, 2013 filed on March 28, 2014. Without limiting the generality of the foregoing, the Company may not be able to complete the private placement because of a number of factors, including the failure to obtain the NASDAQ financial viability exception. Based on current projections, the Company anticipates that, unless by mid-August, 2014, it is reasonably likely that it will be able to obtain additional funding by August 31, 2014, the Company will be forced to initiate steps to cease operations. Even if the financing is consummated, the Company’s future growth plans
may not be successful. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.
Metabolix Inquiries:
Lynne H. Brum, (617) 682-4693, LBrum@metabolix.com
(FINANCIAL TABLES FOLLOW)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
UNAUDITED
(in thousands, except share and per share data)
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
June 30, |
|
June 30, |
| ||||||||
|
|
|
2014 |
|
2013 |
|
2014 |
|
2013 |
| ||||
|
Revenue: |
|
|
|
|
|
|
|
|
| ||||
|
Product revenue |
|
$ |
662 |
|
$ |
822 |
|
$ |
1,201 |
|
$ |
1,611 |
|
|
Grant revenue |
|
483 |
|
584 |
|
950 |
|
1,308 |
| ||||
|
Research and development revenue |
|
— |
|
238 |
|
— |
|
618 |
| ||||
|
License fee and royalty revenue |
|
25 |
|
62 |
|
88 |
|
111 |
| ||||
|
Total revenue |
|
1,170 |
|
1,706 |
|
2,239 |
|
3,648 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Costs and expenses: |
|
|
|
|
|
|
|
|
| ||||
|
Cost of product revenue |
|
774 |
|
1,196 |
|
1,469 |
|
1,753 |
| ||||
|
Research and development expenses |
|
4,479 |
|
4,945 |
|
9,379 |
|
9,802 |
| ||||
|
Selling, general, and administrative expenses |
|
3,156 |
|
3,422 |
|
6,790 |
|
6,734 |
| ||||
|
Total costs and expenses |
|
8,409 |
|
9,563 |
|
17,638 |
|
18,289 |
| ||||
|
Loss from operations |
|
(7,239 |
) |
(7,857 |
) |
(15,399 |
) |
(14,641 |
) | ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Other income (expense): |
|
|
|
|
|
|
|
|
| ||||
|
Interest income, net |
|
2 |
|
12 |
|
7 |
|
33 |
| ||||
|
Other income (expense), net |
|
— |
|
(21 |
) |
2 |
|
(20 |
) | ||||
|
Total other income (expense), net |
|
2 |
|
(9 |
) |
9 |
|
13 |
| ||||
|
Net loss |
|
$ |
(7,237 |
) |
$ |
(7,866 |
) |
$ |
(15,390 |
) |
$ |
(14,628 |
) |
|
|
|
|
|
|
|
|
|
|
| ||||
|
Net loss per share: |
|
|
|
|
|
|
|
|
| ||||
|
Basic |
|
$ |
(0.21 |
) |
$ |
(0.23 |
) |
$ |
(0.44 |
) |
$ |
(0.43 |
) |
|
Diluted |
|
$ |
(0.21 |
) |
$ |
(0.23 |
) |
$ |
(0.44 |
) |
$ |
(0.43 |
) |
|
|
|
|
|
|
|
|
|
|
| ||||
|
Number of shares used in per share calculations: |
|
|
|
|
|
|
|
|
| ||||
|
Basic |
|
34,989,142 |
|
34,434,271 |
|
34,898,473 |
|
34,393,998 |
| ||||
|
Diluted |
|
34,989,142 |
|
34,434,271 |
|
34,898,473 |
|
34,393,998 |
| ||||
METABOLIX, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
UNAUDITED
(in thousands)
|
|
|
June 30, |
|
December 31, |
| ||
|
|
|
2014 |
|
2013 |
| ||
|
Assets |
|
|
|
|
| ||
|
Cash, cash equivalents |
|
$ |
5,531 |
|
$ |
7,698 |
|
|
Short-term investments |
|
— |
|
11,511 |
| ||
|
Inventory |
|
3,162 |
|
4,074 |
| ||
|
Other current assets |
|
1,408 |
|
1,948 |
| ||
|
Restricted cash |
|
619 |
|
619 |
| ||
|
Property and equipment, net |
|
560 |
|
793 |
| ||
|
Other assets |
|
95 |
|
95 |
| ||
|
Total assets |
|
$ |
11,375 |
|
$ |
26,738 |
|
|
|
|
|
|
|
| ||
|
Liabilities and Stockholders’ Equity |
|
|
|
|
| ||
|
Accounts payable and accrued liabilities |
|
$ |
3,634 |
|
$ |
5,471 |
|
|
Short-term deferred revenue |
|
727 |
|
669 |
| ||
|
Current portion of deferred rent |
|
— |
|
55 |
| ||
|
Other long-term liabilities |
|
150 |
|
145 |
| ||
|
Total liabilities |
|
4,511 |
|
6,340 |
| ||
|
Total stockholders’ equity |
|
6,864 |
|
20,398 |
| ||
|
Total liabilities and stockholders’ equity |
|
$ |
11,375 |
|
$ |
26,738 |
|
METABOLIX, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
UNAUDITED
(in thousands)
|
|
|
Six Months Ended June 30, |
| ||||
|
|
|
2014 |
|
2013 |
| ||
|
Cash flows from operating activities |
|
|
|
|
| ||
|
Net loss |
|
$ |
(15,390 |
) |
$ |
(14,628 |
) |
|
Adjustments to reconcile net loss to cash used in operating activities: |
|
|
|
|
| ||
|
Depreciation |
|
333 |
|
531 |
| ||
|
Charge for 401(k) company common stock match |
|
259 |
|
268 |
| ||
|
Stock-based compensation |
|
1,379 |
|
1,677 |
| ||
|
Inventory impairment |
|
228 |
|
271 |
| ||
|
Changes in operating assets and liabilities: |
|
|
|
|
| ||
|
Inventory |
|
684 |
|
(263 |
) | ||
|
Accounts payable |
|
(147 |
) |
(1,131 |
) | ||
|
Accrued expenses |
|
(1,740 |
) |
(345 |
) | ||
|
Deferred revenue |
|
58 |
|
(538 |
) | ||
|
Other operating assets and liabilities |
|
490 |
|
(136 |
) | ||
|
Net cash used in operating activities |
|
(13,846 |
) |
(14,294 |
) | ||
|
|
|
|
|
|
| ||
|
Cash flows from investing activities |
|
|
|
|
| ||
|
Purchase of property and equipment |
|
(100 |
) |
(270 |
) | ||
|
Change in restricted cash |
|
— |
|
(25 |
) | ||
|
Purchase of investments |
|
(1,508 |
) |
(10,580 |
) | ||
|
Proceeds from sale and maturity of short-term investments |
|
13,019 |
|
22,509 |
| ||
|
Net cash provided by investing activities |
|
11,411 |
|
11,634 |
| ||
|
|
|
|
|
|
| ||
|
Cash flows from financing activities |
|
|
|
|
| ||
|
Proceeds from options exercised |
|
300 |
|
14 |
| ||
|
Net cash provided by financing activities |
|
300 |
|
14 |
| ||
|
|
|
|
|
|
| ||
|
Effect of exchange rate changes on cash and cash equivalents |
|
(32 |
) |
(18 |
) | ||
|
|
|
|
|
|
| ||
|
Net (decrease) in cash and cash equivalents |
|
(2,167 |
) |
(2,664 |
) | ||
|
Cash and cash equivalents at beginning of period |
|
7,698 |
|
14,572 |
| ||
|
Cash and cash equivalents at end of period |
|
$ |
5,531 |
|
$ |
11,908 |
|